Posted by Michael Wonder on 12 Oct 2022
Lutetium Lu 177 vipivotide tetraxetan for treating PSMA positive hormone relapsed metastatic prostate cancer after two or more therapies
12 October 2022 - The Department of Health and Social Care has asked the NICE to produce guidance on using lutetium Lu 177 vipivotide tetraxetan in the NHS in England.
Lutetium Lu177 vipivotide tetraxetan is not recommended for the treatment of adults with prostate-specific membrane antigen (PSMA) positive hormone relapsed metastatic prostate cancer after the use of taxane-based chemotherapy and an anti-androgen or when the use of a taxane is medically unsuitable.
